



Final Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
5 - 7 November 2013
CCV/CICG, Geneva

Tuesday, 5 November 2013

Time	Session	Purpose of session, target outcomes and questions for SAGE	
9:00	Welcome - introduction J. Abramson, Chair of SAGE		20 min.
9:20	Global report from Director, IVB – Session 1 Global report including key updates and challenges from regions, J.-M. Okwo-Bele, WHO, 30 min. Discussion: 1 hr.	FOR INFORMATION	1h 30 min.
10:50	Coffee/tea break	Break	30 min.
11:20	Report from GAVI – Session 2 Report from the GAVI Alliance, S. Berkley, GAVI Alliance, 20 min. Discussion: 20 min.	FOR INFORMATION	40 min.

12:00	<p>Reports from other Advisory Committees on Immunization - Session 3</p> <p>Report of the Expert Committee on Biological Standards (ECBS), E. Griffiths, Chair of ECBS, 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Global Advisory Committee on Vaccine Safety (GACVS), M. Wharton, Chair of GACVS, 10 min.</p> <p>Discussion on GACVS report and specific discussion on vaccination of pregnant and lactating women: 40 min.</p>	FOR INFORMATION AND DISCUSSION	2h
13:10	Lunch	Break	1h
14:10	<p>Reports from other Advisory Committees on Immunization - Session 3, (Contd.)</p> <p>Report of the Immunization Practices Advisory Committee (IPAC), S. Deeks, Chair of IPAC, 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Immunization and Vaccine related Implementation Research (IVIR-AC) Advisory Committee, R. Breiman, Chair of IVIR, 10 min.</p> <p>Discussion: 20 min.</p>		
15:00	<p>Global polio eradication initiative - Session 4</p> <p>Major developments and progress in polio eradication and issues for SAGE decisions and discussions. B. Aylward, WHO, 10 min.</p> <p>Discussion: 10 min.</p> <p>Progress of Polio Eradication and Endgame Strategy Plan : detection and interruption of poliovirus transmission. H. Jafari, WHO, 20 min.</p> <p>Discussion: 30 min.</p>	<p>FOR DISCUSSION AND DECISION</p> <p>For decision:</p> <ul style="list-style-type: none"> • Optimal schedule for 1 IPV dose • Strategic framework for responding to type 2 virus detection post-OPV2 cessation • Recommendation for a WHA resolution in 2014 on accelerated IPV introduction, based on the progress toward a global supply and financing strategy <p>For discussion:</p> <ul style="list-style-type: none"> • Strategy to ensure bOPV access to all OPV-using countries 	3h 30 min.

		<ul style="list-style-type: none"> Criteria to assess global readiness for global OPV2 withdrawal 	
16:10	Coffee/tea break	Break	30 min.
16:40	<p>Global polio eradication initiative - Session 4, (Contd.)</p> <p>Planning for OPV2 withdrawal: the report from the Polio Working Group. E. Miller, Chair of SAGE Polio Working Group, 20 min.</p> <p>Discussion: 60 min.</p> <p>IPV supply, financing and introduction strategy in priority countries. M. Zaffran, WHO, 10 min.</p> <p>Discussion: 20 min.</p> <p>Post-OPV2 cessation type II poliovirus outbreak response strategy. H. Jafari, WHO, 10 min.</p> <p>Discussion: 20 min.</p>		
19:00	Cocktail		

Wednesday, 6 November 2013

Time	Session	Purpose of session, target outcomes and questions for SAGE	
8:30	<p>Decade of Vaccines - Global Vaccine Action Plan (GVAP) Monitoring - Session 5</p> <p>The GVAP annual progress report: the process, data sources and data quality, Secretariat of the Decade of Vaccines Working Group, T. Cherian, WHO, 20 min.</p> <p>Summary of GVAP implementation progress, R. Martin, Member of the Decade of Vaccines Working Group, 20 min.</p> <p>Recommendations for corrective actions, N. Arora, Chair of the Decade of Vaccines Working Group, 20 min.</p> <p>Discussion: 90 min.</p>	<p>FOR DECISION</p> <p>SAGE will be expected to produce an independent first report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> - Review the DoV WG "Assessment report on DoV progress" based on: <ul style="list-style-type: none"> • the review of the "annual report on the Decade of Vaccines progress" prepared by the DOV secretariat, • Information provided by other partners' annual reports on Decade of Vaccines progress. - Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection. - Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed. - Provide recommendations and corrective actions for Members States, regions, partners, donor agencies or other parties regarding DoV GVAP implementation in a "SAGE Assessment report on the Decade of Vaccines progress" which will be the basis of the "progress report" for the WHO Board and World Health Assembly. 	2h 30 min.
11:00	Coffee/tea break	Break	30 min.
11:30	<p>Pandemic and pre-pandemic influenza vaccine - Session 6</p> <p>Update on H7N9 epidemiologic situation and vaccine development, W. Zhang, WHO, 10 min.</p> <p>Discussion: 10 min.</p> <p>Review of evidence on H5N1, J. Bresee, (By telephone connection), member of the influenza Working Group, 15 min.</p>	<p>FOR INFORMATION AND FOR DECISION</p> <p>For information</p> <p>An update on the epidemiology of H7N9 and progress on vaccine development will also be provided. SAGE will be asked to discuss information to be collected on H7N9 cases of emerging virus in order to facilitate policy recommendations</p>	1h 30 min.

	<p>Conclusions and recommendations from the influenza Working Group on the H5N1 stockpile and on pre-pandemic use of H5N1 vaccine, L. Miller, Chair of the influenza Working Group, 15 min.</p> <p>Discussion: 40 min.</p>	<p>For decision</p> <p>In the context of the Pandemic Influenza Preparedness framework, review the previous recommendations on the establishment and use of an H5N1 vaccine stockpile</p> <p>Review the current recommendations on inter-pandemic use of H5N1 vaccines.</p>	
13:00	Lunch	Break	1h
14:00	<p>Measles and rubella elimination - Session 7</p> <p>Update on progress and challenges in achieving measles and rubella targets. P. Strebel, WHO, 15 min.</p> <p>Discussion: 30 min.</p> <p>Recommendations for introducing rubella vaccine into the routine vaccination schedule and determining the target age range for measles and combined measles-rubella SIAs. P. Figueroa, Chair of the Measles and Rubella Working Group, 20 min.</p> <p>Discussion: 40 min</p> <p>Recommendations for vaccination of health workers, S. Reef, Member of the Measles and Rubella Working Group, 10 min.</p> <p>Discussion: 25 min.</p>	<p>FOR DISCUSSION AND DECISION</p> <p>For discussion:</p> <ul style="list-style-type: none"> • Global status report • Report from each Region • How to get back on track towards global and Regional targets <p>For decision:</p> <ul style="list-style-type: none"> • Use of combined measles-rubella vaccine for both routine doses • Criteria to guide countries on expansion of the target age range measles and measles-rubella SIAs <p>For decision:</p> <ul style="list-style-type: none"> • Vaccination of health workers 	3h
16:20	Coffee/tea break	Break	30 min.
16:50	<p>Measles and rubella elimination - Session 7 (Contd.)</p> <p>Prioritizing the research agenda for measles and rubella W. Moss, Member of the Measles and Rubella Working Group, 15 min.</p> <p>Discussion: 25 min.</p>	<p>For discussion:</p> <ul style="list-style-type: none"> • List of priority research topics 	

17:30	<p>Smallpox vaccines - Session 8</p> <p>WHO Smallpox vaccine emergency stockpile and production, A. Costa, WHO, 10 min.</p> <p>Review of efficacy and safety of smallpox vaccines, H. Meyer, member of the expert consultation, Paul Ehrlich Institute, Germany, 15min.</p> <p>Conclusions and recommendations from the Expert Consultation, Y. Al-Mazrou, Chair of the Expert Consultation, 15 min.</p> <p>Discussion: 50 min.</p>	<p>FOR DECISION</p> <p>The last case of Smallpox occurred in 1977. In 1980 the World Health Assembly declared this disease eradicated. A global stockpile of vaccines, held in Switzerland, was created with donations from Member States.</p> <p>In 2004 Previous the Ad-Hoc Orthopoxvirus Committee, recommended that the stockpile should consist 200 million doses. The current physical WHO stockpile is ~ 2.4 million doses, and the virtual stockpile consists of 31 million doses.</p> <p>In order for WHO to make an informed decision (risk-benefit) on which vaccines to stock and to be able to give advice to countries on their stockpile, WHO would like SAGE to answer the following questions:</p> <p>Which vaccine should be recommended to be used during an outbreak of smallpox? (vaccine used during the eradication, vaccine produced in tissue cell, or further attenuated vaccines).</p> <ul style="list-style-type: none"> –Composition of stockpile –Size of stockpile <p>What groups should be prioritized to be vaccinated while faced with limited vaccine supply?</p> <ul style="list-style-type: none"> –Age groups, risk factors/safety aspects, vulnerable populations, ethical considerations –Which vaccine should be given? <p>Which vaccine should be recommended for preventive use? Who should be targeted and with which immunization schedule? (First aid responders, army, police, health workers)</p>	1h 30 min.
19:00	End of day		

Thursday, 7 November 2013

Time	Session	Purpose of session, target outcomes and questions for SAGE	
8:30	Immunization supply chain & logistics : key challenges and future direction - Session 9 A story about the supply chain challenges in country, J. Vandelaer, UNICEF, 10 min. The key supply chain challenges, J. Vandelaer, UNICEF, 10 min. Mechanisms in place to address some of the challenges and key take-home messages, D. Chang-Blanc, WHO, 10 min. Discussion: 30 min.	FOR INFORMATION The purpose of this session is to highlight the ongoing constraints faced by country supply chains for vaccines, and provide evidence of the mounting challenges of introducing more vaccines into currently stretched systems. It will provide insight as to how WHO and UNICEF are enhancing their collaboration to support countries strengthen their immunization supply chain systems for the future.	1h
9:30	Sentinel site surveillance - Session 10 Strategic review of the IB-VPD surveillance network: key findings, conclusions and recommendations, C. Broome, informal Technical Advisory Group Chair, 15 min. Strategic review of the rotavirus surveillance network: key findings, conclusions and recommendations, G. Kang, informal Technical Advisory Group Co-Chair, 15 min. Moving forward after the strategic review: Next steps & future vision, T. Cherian, WHO, 10 min.	FOR DISCUSSION To seek SAGE guidance on the results of a strategic review of the global rotavirus and invasive bacterial vaccine preventable diseases (IB-VPD) sentinel hospital networks, both of which use a case-based approach with laboratory confirmation of cases; To seek SAGE advice on the utility of these global coordinated surveillance networks to provide data for public health decision makers; To seek SAGE guidance on the suitability of these networks as platforms for surveillance for other VPDs.	1h 30 min.
10:10	Coffee/tea break	Break	30 min.
10:40	Sentinel site surveillance – Session 10 (Contd.) Discussion: 50 min.	FOR DISCUSSION	
11:30	Closing		
12:00	End of meeting		